Infrequent Tumors of the Gastrointestinal Tract Including Gastrointestinal Stromal Tumor (GIST)

PET Clinics

Volumn 3, Issue 2, 2008, Pages 207-215

  Ertuk, Mehmet ^a   Van den Abbeele, Annick D ^b,c,d  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

Computed tomography; F 18 fluorodeoxyglucose; Gallbladder cancer; Gastric lymphoma; Gastrointestinal stromal tumor; Imatinib; Intrapapillary mucinous neoplasm of the pancreas; Positron emission tomography; Sunitinib

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; SUNITINIB;

CHOLECYSTECTOMY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; ECHOGRAPHY; ENDOSCOPIC BIOPSY; GALLBLADDER CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INTERMETHOD COMPARISON; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH LYMPHOMA; TUMOR LOCALIZATION;

EID: 64749108981     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2008.10.002     Document Type: Review

References (60)

1. Esteves F.P., Schuster D.M., and Halkar R.K. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med 36 2 (2006) 169-181
2. Warburg O. The Metabolism of Tumours. Investigations from the Kaiser-Wilhelm Institute for Biology, Berlin-Dahlem (1930), Constable & Co. Ltd., London
3. Bui T., and Thompson C.B. Cancer's sweet tooth [comment]. Cancer Cell 9 6 (2006) 419-420
4. Mazur M.T., and Clark H.B. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 7 6 (1983) 507-519
5. Kindblom L.G., Aldenborg F., Meis-Kindblom J.M., et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152 5 (1998) 1259-1269
6. Hirota S., Isozaki K., Nishida T., et al. Effects of loss-of-function and gain-of-function mutations of c-kit on the gastrointestinal tract. J Gastroenterol 35 Suppl 12 (2000) 75-79
7. Bucher P., Villiger P., Egger J.F., et al. Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Med Wkly 134 11-12 (2004) 145-153
8. Miettinen M., and Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438 1 (2001) 1-12
9. Blanchard D.K., Budde J.M., Hatch G.F., et al. Tumors of the small intestine. World J Surg 24 4 (2000) 421-429
10. Lau S., Tam K.F., Kam C.K., et al. Imaging of gastrointestinal stromal tumour (GIST). Clin Radiol 59 6 (2004) 487-498
11. Connolly E.M., Gaffney E., and Reynolds J.V. Gastrointestinal stromal tumours. Br J Surg 90 10 (2003) 1178-1186
12. DeMatteo R.P. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 9 9 (2002) 831-839
13. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach [see comment]. Hum Pathol 33 5 (2002) 459-465
14. Lux M.L., Rubin B.P., Biase T.L., et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156 3 (2000) 791-795
15. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 22 18 (2004) 3813-3825
16. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 23 (2003) 4342-4349
17. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 5607 (2003) 708-710
18. Hirota S., Ohashi A., Nishida T., et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125 3 (2003) 660-667
19. Heinrich M.C., Corless C.L., Blanke C.D., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24 29 (2006) 4764-4774
20. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 9544 (2006) 1329-1338
21. Van den Abbeele A.D., for the GIST Collaborative PET Study Group (Dana-Farber Cancer Institute, Boston, Massachusetts; OHSU, Portland, Oregon, Helsinki University Central Hospital, Turku University Central Hospital, Finland, and Novartis Oncology). F18-FDG-PET provides early evidence of biological response to ST15171 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 20 (2001) 362a
22. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
23. Van den Abbeele A.D., and Badawi R.D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38 Suppl 5 (2002) S60-S65
24. Dagher R., Cohen M., Williams G., et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8 10 (2002) 3034-3038
25. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group. Eur J Cancer 35 13 (1999) 1773-1782
26. Holdsworth CH, Manola J, Badawi RD, et al. Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 3011, 2004. 22(14S (July 15 Supplement)): p. 3011.
27. Stroobants S., Seegers M., Goeminne J., et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39 (2003) 2012-2020
28. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25 13 (2007) 1753-1759
29. Heinicke T., Wardelmann E., Sauerbruch T., et al. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res 25 6C (2005) 4591-4594
30. Jager P.L., Gietema J.A., and van der Graaf W.T. Imatinib mesylate fro the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 25 5 (2004) 433-438
31. Goerres G.W., Stupp R., Barghouth G., et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32 2 (2005) 153-162
32. Antoch G., Kanja J., Bauer S., et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (ST1571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45 3 (2004) 357-365
33. Holdsworth C.H., Badawi R.D., Manola J.B., et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 189 6 (2007) W324-W330
34. Van den Abbeele A.D., Badawi R., Manola J., et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. Proc Am Soc Clin Oncol 22 (2004) 3012
35. Hirooka Y., Naitoh Y., Goto H., et al. Differential diagnosis of gall-bladder masses using colour Doppler ultrasonography. J Gastroenterol Hepatol 11 9 (1996) 840-846
36. Oe A., Kawabe J., Torii K., et al. Distinguishing benign from malignant gallbladder wall thickening using FDG-PET. Ann Nucl Med 20 10 (2006) 699-703
37. Shukla H.S. Gallbladder cancer. J Surg Oncol 93 8 (2006) 604-606
38. Rodriguez-Fernandez A., Gomez-Rio M., Llamas-Elvira J.M., et al. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis. Am J Surg 188 2 (2004) 171-175
39. Anderson C.D., Rice M.H., Pinson C.W., et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 8 1 (2004) 90-97
40. Radan L., Fischer D., Bar-Shalom R., et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging 35 8 (2008) 1424-1430
41. d'Amore F., Brincker H., Gronbaek K., et al. Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish lymphoma study group. J Clin Oncol 12 8 (1994) 1673-1684
42. Akwaa A., Siddiqui N., and Al-Mofleh I. Primary gastric lymphoma. World J Gastroenterol 10 (2004) 5-11
43. Zucca E., Conconi A., and Cavalli F. Treatment of extranodal lymphomas. Best Pract Res Clin Haematol 15 3 (2002) 533-547
44. Ambrosini V., Rubello D., Castellucci P., et al. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma. Nucl Med Rev Cent East Eur 9 1 (2006) 37-40
45. Kumar R., Xiu Y., Potenta S., et al. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med 45 11 (2004) 1796-1803
46. Phongkitkarun S., Varavithya V., Kazama T., et al. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose. World J Gastroenterol 11 46 (2005) 7284-7289
47. Beal K.P., Yeung H.W., and Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 16 3 (2005) 473-480
48. Schoder H., Noy A., Gonen M., et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23 21 (2005) 4643-4651
49. Hoffmann M., Kletter K., Becherer A., et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 64 4 (2003) 336-340
50. Even-Sapir E., Lievshitz G., Perry C., et al. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with non-Hodgkin's lymphoma and Hodgkin's disease. PET Clin N Am 1 (2006) 251-263
51. Metser U., Goor O., Lerman H., et al. PET-CT of extranodal lymphoma. AJR Am J Roentgenol 182 6 (2004) 1579-1586
52. Baiocchi G.L., Portolani N., Bertagna F., et al. Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results. J Exp Clin Cancer Res 27 (2008) 10
53. Fernandez-del Castillo C., and Warshaw A.L. Cystic tumors of the pancreas. Surg Clin North Am 75 5 (1995) 1001-1016
54. Goh B.K., Chung Y.F., Ng D.C., et al. Positron emission tomography with 2-deoxy-2-[18f] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas. JOP 8 3 (2007) 350-354
55. Jang J.Y., Kim S.W., Ahn Y.J., et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery?. Ann Surg Oncol 12 2 (2005) 124-132
56. Goh B.K., Tan Y.M., Cheow P.C., et al. Cystic lesions of the pancreas: an appraisal of an aggressive resectional policy adopted at a single institution during 15 years. Am J Surg 192 2 (2006) 148-154
57. Sperti C., Pasquali C., Chierichetti F., et al. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg 234 5 (2001) 675-680
58. Sperti C., Pasquali C., Decet G., et al. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg 9 1 (2005) 22-28 [discussion 28-9]
59. Yoshioka M., Sato T., Furuya T., et al. Positron emission tomography with 2-deoxy-2-[(18)F] fluoro-d-glucose for diagnosis of intraductal papillary mucinous tumor of the pancreas with parenchymal invasion. J Gastroenterol 38 12 (2003) 1189-1193
60. Mansour J.C., Schwartz L., Pandit-Taskar N., et al. The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg 10 10 (2006) 1354-1360